The Institute for Clinical and Economic Review (ICER) on Friday released a draft evidence report analyzing the effectiveness and value of medications for addiction treatment used to support patients with opioid use disorder.
According to a press release, ICER analyzed the following drugs:
- Titan’s buprenorphine implant;
- Alkermes Vivitrol, an extended-release naltrexone injection; and
- Indivior’s Sublocade and Braeburn’s CAM2038, both of which are extended-release buprenorphine injections.
ICER’s report will be discussed at the Nov. 8 meeting of the New England Comparative Effectiveness Public Advisory Council.
Public comments are open until 5 p.m. EST Oct. 4.
To read the full press release, click here.